

Company Registration No 6675642 (England & Wales)
Charity Registration Number 1127495

BARRETT'S OESOPHAGUS CAMPAIGN

REPORT AND ACCOUNTS

FOR THE YEAR ENDED 30 SEPTEMBER 2010

BARRETT'S OESOPHAGUS CAMPAIGN

CONTENTS

	Page
LEGAL AND ADMINISTRATIVE INFORMATION	1
DIRECTORS' AND TRUSTEES' REPORT	3
STATEMENT OF FINANCIAL ACTIVITIES	8
BALANCE SHEET	9
NOTES TO THE ACCOUNTS	10
PRESENTATIONS AND PUBLICATIONS (UKBOR)	18

BARRETT'S OESOPHAGUS CAMPAIGN

LEGAL AND ADMINISTRATIVE INFORMATION

Patron	Lord Darzi of Denham PC KBE
Vice-Presidents	Professor Sir Ian Gilmore MD PRCP Lord Ribeiro CBE PRCS Professor Dame Carol Black DBE MD FRCP The Rt Hon David Blunkett MP Martyn Lewis CBE Lord Turnberg of Cheadle MD FRCP FmedSci Professor Robin Williamson FRCS
Trustee Directors	Dr P R Salmon – Chairman BSc (Hons) MB MRCS(Engl) FRCP(Lond) FRCP(Ed) Dr P I Reed MB FRCP FRCPC Professor Anthony Watson MD FRCS(Engl) FRCS(Ed) FRACS Mr A Vallance-Owen FRCS MBA Mr Chris Robinson
Principal office	UK National Barrett's Oesophagus Registry UCL, Division of Surgery and Interventional Science Royal Free Campus Royal Free and University College Medical School Rowland Hill Street London NW3 2PF Telephone: 020 7472 6223 Facsimile: 020 7471 6224
Registrar of UKBOR	Dr C P J Caygill BSc PhD
Charity registration number	1127495

BARRETT'S OESOPHAGUS CAMPAIGN

LEGAL AND ADMINISTRATIVE INFORMATION (CONTINUED)

Reporting accountants	SRLV 89 New Bond Street London W1S 1DA
Bankers	Coutts & Co 440 Strand London WC1R 0QS
Solicitors	Bircham Dyson Bell LLP 50 Broadway London SW1H 0BL
Company Secretary	Nexus Management Services Limited 2 nd Floor, Griffin House West Street Woking Surrey GU21 6BS Telephone: 01483 749020 Facsimile: 01483 749021
Company registered office	2 nd Floor, Griffin House West Street Woking Surrey GU21 6BS

BARRETT'S OESOPHAGUS CAMPAIGN

DIRECTORS' AND TRUSTEES' REPORT FOR THE YEAR ENDED 30 SEPTEMBER 2010

The directors present their report and accounts for the year ended 30 September 2010.

The directors have adopted the relevant provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" issued in October 2005 in preparing their report and accounts for the period.

The comparative figures provided in this report and accounts are for the period from 18 August 2008 (the date of the company's incorporation) to 30 September 2009.

Reference and administrative details

Reference and administrative details are shown on pages 1 to 2 of this report and accounts.

Structure, governance and management

The charity was incorporated on 18 August 2008 as a company limited by guarantee and is governed by its memorandum and articles of association dated on that date.

The directors, who are also trustees of the charity, who served during the year, were:

	Date of appointment	Date of resignation
Dr P R Salmon (Chairman)	03.12.2008	
Dr P I Reed	03.12.2008	
Prof. A Watson	03.08.2010	
Mr C Robinson	03.08.2010	
Mr H A Hyman	03.12.2008	01.04.2011
Dr RC Fitzgerald	03.12.2008	30.07.2010
Mr T Thornton-Jones	03.12.2008	30.07.2010
Ms Belinda Johnston BSc	01.01.2009	30.07.2010
Mr C V Marchant-White	03.12.2008	09.02.2010
Mrs M McCord	03.12.2008	09.02.2010

Mr. A Vallance-Owen was appointed a director and trustee of the charity on 31 March 2011.

Trustees will serve a three-year term deemed to run from the beginning of the calendar year in which they were appointed and conclude at the first board meeting held after their third anniversary as trustees.

None of the directors has any beneficial interest in the company. All of the directors are members of the company and have guaranteed to contribute £1 each in the event of a winding up.

The charity ensures that the trustees are fully aware of their duties and responsibilities which are discussed at the regular meetings of the board.

BARRETT'S OESOPHAGUS CAMPAIGN

DIRECTORS' AND TRUSTEES' REPORT (continued) FOR THE YEAR ENDED 30 SEPTEMBER 2010

Risk management

The directors have assessed the major risks to which the charity is exposed, and are satisfied that systems are in place to mitigate exposure to the major risks. The board will continually monitor the risks to which the charity is exposed and implement procedures to minimise the potential impact of those risks.

Reserves policy

Except for such funds as the trustees consider prudent to maintain for the purposes of management and administration of the charity for the foreseeable future, all unrestricted funds are for the purposes of the general charitable objects of the charity.

The trustees regularly monitor and review the level of reserves in the light of available and projected funds and income and expenditure relating to planned activities.

Objectives and activities

The Barrett's Oesophagus Campaign is the only charity whose main objective is related to prevention of oesophageal cancer.

'Barrett's oesophagus' is a pre-cancerous condition of the oesophagus (gullet) arising as a consequence of prolonged regurgitation (reflux) of acid and bile from the stomach into the oesophagus, the lining of which in consequence alters its characteristics which in a proportion of sufferers can undergo malignant change and lead to the development of a type of cancer of the oesophagus (adenocarcinoma) with a relatively poor outlook. The incidence of both Barrett's oesophagus and adenocarcinoma of the oesophagus and gastric cardia is increasing in many countries including the United Kingdom.

Because the natural history of Barrett's oesophagus and of its most important complication, adenocarcinoma of the oesophagus, is still not clearly understood, much more data are required to formulate the best way of treating Barrett's oesophagus and preventing adenocarcinoma.

The United Kingdom National Barrett's Oesophagus Registry (UKBOR) was started in 1996 with a very generous donation from a non-medical charity supplemented by other contributions from charities and patients with Barrett's oesophagus. UKBOR now has the largest database of Barrett's oesophagus patients in the world with over 12,000 patients from 45 centres. The results of its research have been published and presented nationally and internationally and several European countries plan to develop national registries based on the UK model.

The Barrett's Oesophagus Campaign exists to:

- Secure the long-term future of UKBOR
- Provide a support and education service for patients and relatives of patients with Barrett's oesophagus and associated adenocarcinoma of the oesophagus and gastric cardia;
- Make research awards and project grants for research in the field of Barrett's oesophagus in the United Kingdom.

BARRETT'S OESOPHAGUS CAMPAIGN

DIRECTORS' AND TRUSTEES' REPORT (continued) FOR THE YEAR ENDED 30 SEPTEMBER 2010

Achievements and performance

The 2010 financial year has been one of transition for the charity. Due to a divergent nature of opinion on the charity's board of trustees as to the charity's future strategic direction, it was considered in the best interest of the charity for a demerger to occur, effectively undoing the original merger between the charity and the McCord Oesophageal Cancer Foundation ('MOCF'). A new entity, Heartburn Cancer Awareness & Support ("HCAS"), was established, to which the assets originally transferred to the charity by MOCF were transferred and agreement was reached as to the division of assets generated since the merger. A number of trustees resigned to join the newly established entity. The demerger was effected on 30 July 2010.

The demerger was time consuming (significant business having had to be put on hold since late 2009) and costly, but has left the charity with freedom to move forwards in pursuit of its objects (including the support of UKBOR). The charity has subsequently made significant advances predominantly through UKBOR, which was the only overseas centre to be invited to join a consortium of American centres, led by Harvard University, to mount a research programme on Barrett's Oesophagus to be placed before the National Institutes of Health in Washington DC. Also in 2009-10, UKBOR made three presentations of its research at international scientific conferences and had three original research papers published in international peer reviewed medical research publications.

Financial review

During the year, total incoming resources of the charity amounted to £92,631 (2009: £35,312 excluding resources of £161,588 transferred from The Barrett's Oesophagus Foundation to the company). From this, total resources expended during the year amounting to £153,784 (2009: £112,867) were deducted, resulting in net outgoing resources of £61,153 (2009: £77,555) for the year. Demerged funds of £56,306 representing net assets transferred to HCAS as a part of the demerger agreement mentioned above, have also been deducted leaving a deficit of £33,426 to be carried forward at the year end.

The demerger has severely depleted the funds of the charity. The directors are confident however that, with regular and careful monitoring of its financial situation and their continued financial support, it will enable the charity to pay its liabilities as and when they fall due. They are also confident that the charity will recover from its current financial situation and return to positive reserves in the near future. The directors are therefore of the opinion that the preparation of the financial statements for the year on a going concern basis is wholly appropriate.

BARRETT'S OESOPHAGUS CAMPAIGN

DIRECTORS' AND TRUSTEES' REPORT (continued) FOR THE YEAR ENDED 30 SEPTEMBER 2010

Statement of directors' and trustees' responsibilities

The trustees are also directors of the company for the purposes of the Companies Act 2006.

The Directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and the Group and of the profit or loss of the Group for that period. In preparing these financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

In accordance with company and charity legislation, the directors are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the company which enable them to ensure that the financial statements comply with the Companies Act 2006 and the Charities Act 1993. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. The directors as trustees are responsible for ensuring that the Trustees' Report is prepared in accordance with charity law in the United Kingdom.

The directors are responsible for the maintenance and integrity of the Company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

BARRETT'S OESOPHAGUS CAMPAIGN

DIRECTORS' AND TRUSTEES' REPORT (continued) FOR THE YEAR ENDED 30 SEPTEMBER 2010

Small company provisions

These accounts have been prepared in accordance with the provisions in the Companies Act 2006 applicable to companies subject to the small companies' regime.

Audit exemption and reporting accountants

The directors consider that the company is entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. An external independent scrutiny of these accounts was considered unnecessary in the interest of the conservation of the charity's funds. Accordingly the reporting accountants SRLV (formerly Sedley Richard Laurence Voulters) have not carried a review of these accounts and consequently an Accountants' Report has not been included in this report and accounts. SRLV have indicated their willingness to continue in office for the ensuing year.

Approved by the board of directors on 29 June 2011 and signed on its behalf:



For and on behalf of
Nexus Management Services Limited
Secretary

BARRETT'S OESOPHAGUS CAMPAIGN

STATEMENT OF FINANCIAL ACTIVITIES

FOR THE YEAR ENDED 30 SEPTEMBER 2010

	Notes	General Funds £	Restricted Funds £	Year ended 30.09.2010 Total £	Period to 30.09.2009 Total £
INCOMING RESOURCES					
	2				
Voluntary income		15,715	31,091	46,806	34,991
Activities for generating income		42,791	2,987	45,778	-
Investment income		47	-	47	321
Total incoming resources		58,553	34,078	92,631	35,312
Continuing activities		58,553	14,411	72,964	17,777
Discontinued activities		-	19,667	19,667	17,535
Total incoming resources above		58,553	34,078	92,631	35,312
RESOURCES EXPENDED					
	3				
Cost of generating funds		18,300	138	18,438	1,870
Charitable activities		-	58,119	58,119	70,195
Governance costs		77,227	-	77,227	40,802
Total resources expended		95,527	58,257	153,784	112,867
Continuing activities		95,527	30,268	125,795	76,659
Discontinued activities		-	27,989	27,989	36,208
Total resources expended above		95,527	58,257	153,784	112,867
NET INCOMING / (OUTGOING) RESOURCES					
	4				
Continuing activities		(36,974)	(15,856)	(52,830)	(58,882)
Discontinued activities		-	(8,323)	(8,323)	(18,673)
Total net incoming / (outgoing) resources		(36,974)	(24,179)	(61,153)	(77,555)
TRANSFER OF FUNDS FROM BARRETT'S OESOPHAGUS FOUNDATION					
		-	-	-	161,588
TOTAL FUNDS BROUGHT FORWARD		19,144	64,889	84,033	-
DEMERGED FUNDS	9	-	(56,306)	(56,306)	-
TOTAL (DEFICIT)/ FUNDS CARRIED FORWARD		(17,830)	(15,596)	(33,426)	84,033

There were no gains or losses other than the result for the year.

The notes to the accounts on pages 10 to 17 form part of these accounts.

BARRETT'S OESOPHAGUS CAMPAIGN

BALANCE SHEET

Company Registration No. 6675642

AS AT 30 SEPTEMBER 2010

	Notes	2010 £	2009 £
FIXED ASSETS			
Tangible assets		-	27,000
CURRENT ASSETS			
Cash at bank		15,330	87,638
Debtors and prepayments	7	8,395	3,677
		<u>23,725</u>	<u>91,315</u>
CREDITORS			
Amounts falling due within one year	8	(57,151)	34,282
NET CURRENT (LIABILITIES) / ASSETS		<u>(33,426)</u>	<u>57,033</u>
NET (LIABILITIES) / ASSETS		<u>(33,426)</u>	<u>84,033</u>
Represented by:			
FUNDS OF THE CHARITY			
General funds		(17,830)	19,144
Restricted funds	9	(15,596)	64,889
TOTAL (DEFICIT) / FUNDS		<u>(33,426)</u>	<u>84,033</u>

For the year ending 30 September 2010, the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.


The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the Act.

The directors have acknowledged their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the Financial Reporting Standard for Smaller Entities (effective 2008).

The notes to the accounts on pages 10 to 17 form part of these accounts.

Approved by the board and authorised for issue on 29 June 2011



Dr P Salmon
Director

BARRETT'S OESOPHAGUS CAMPAIGN

NOTES TO THE ACCOUNTS

FOR THE YEAR ENDED 30 SEPTEMBER 2010

1. Principal accounting policies

Basis of accounting

The accounts have been prepared under the historical cost convention and in accordance with the requirements of the Charities Act 1993. Accounting standards and provisions of the Statement of Recommended Practice "Accounting and Reporting by Charities" (SORP 2005) applicable to small charities have been followed in these accounts.

The financial statements have been prepared on a going concern basis which assumes that the company will continue to operate. However, the validity of the going concern basis is dependent upon the continued support of the directors and other creditors. If the company is unable to continue to trade, adjustments would be required to reduce the value of assets to their recoverable amounts, to provide for any further liabilities that might arise and to analyse both fixed assets and long term liabilities as current assets and liabilities.

Voluntary income

Donations represent voluntary amounts received during the period and arise within the United Kingdom. Covenanted and Gift-aid income is included gross of attributable tax recoverable.

Investment income

Interest receivable is credited to income in the period in which it is earned and is included gross of attributable tax recoverable.

Expenditure

Expenditure is provided for on the accruals basis. Direct charitable expenditure of the Registry (UKBOR) comprises principally staff costs and sundry running expenses. Management and administration of the charity comprises costs directly attributable to the management of the charity including professional, regulatory and compliance costs.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off the cost of each asset over its estimated useful life:

- Computer equipment - 1 year
- Endoscopy equipment - 5 years

BARRETT'S OESOPHAGUS CAMPAIGN

NOTES TO THE ACCOUNTS (continued) FOR THE YEAR ENDED 30 SEPTEMBER 2010

1. Principal accounting policies (continued)

Fund accounting

General funds comprise the accumulated surplus or deficit on the statement of financial activities. They are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity. Restricted funds are funds subject to specific restricted conditions imposed by donors. The purpose and use of the restricted funds are set out in the notes to the accounts where appropriate. Designated funds are funds which have been set aside at the discretion of the trustees for specific purposes. The purpose and use of the designated unrestricted funds are set out where appropriate in the notes to the accounts.

Taxation

The charity is not liable to direct taxation (income tax) on its income as it falls within the various exemptions available to registered charities. The charity is not registered for value added tax (VAT) and is therefore unable to reclaim the input tax it suffers on its purchases. Expenditure in the accounts is therefore shown inclusive of VAT where appropriate.

BARRETT'S OESOPHAGUS CAMPAIGN

NOTES TO THE ACCOUNTS (continued) FOR THE YEAR ENDED 30 SEPTEMBER 2010

2. Analysis of incoming resources

	General Funds £	Restricted Funds £	Year ended 30.09.2010 Total £	Period to 30.09.2009 Total £
Voluntary income				
Donations received	12,224	31,091	43,315	34,717
Gift aid claimed	3,491	-	3,491	244
PROBE membership fees	-	-	-	30
	<u>15,715</u>	<u>31,091</u>	<u>46,806</u>	<u>34,991</u>
Activities for generating income				
Income from fundraising events	42,791	2,987	45,778	-
Investment income				
Bank interest receivable	47	-	47	321
	<u>58,553</u>	<u>34,078</u>	<u>92,631</u>	<u>35,312</u>
Incoming resources from discontinued activities included above:				
Voluntary income				
Donations received	-	19,667	19,667	17,535
	<u>-</u>	<u>19,667</u>	<u>19,667</u>	<u>17,535</u>

The Royal Free Hospital Hampstead NHS Trust provides office accommodation on a rent-free basis.

BARRETT'S OESOPHAGUS CAMPAIGN

NOTES TO THE ACCOUNTS (continued) FOR THE YEAR ENDED 30 SEPTEMBER 2010

3. Analysis of resources expended

	General Funds £	Restricted Funds £	Year ended 30.09.2010 Total £	Period to 30.09.2009 Total £
Cost of generating funds				
Fundraising events costs	15,840	138	15,978	-
Fundraising consultancy	2,391	-	2,391	1,714
CAF and Just Giving charges	69	-	69	156
	<u>18,300</u>	<u>138</u>	<u>18,438</u>	<u>1,870</u>
Charitable activities				
Registry staff costs	-	19,550	19,550	21,345
Patient information & website maintenance	-	6,222	6,222	6,519
Conferences	-	3,982	3,982	3,631
Travelling expenses	-	876	876	1,992
Total UKBOR costs	-	30,630	30,630	33,487
Twort awards	-	2,383	2,383	2,000
McCord grant	-	12,500	12,500	17,500
Barrett's Wessex grant	-	(500)	(500)	500
Depreciation of endoscopy equipment	-	7,500	7,500	9,000
Maintenance of endoscopy equipment	-	5,606	5,606	7,708
	-	<u>58,119</u>	<u>58,119</u>	<u>70,195</u>
Governance costs				
Office and administration costs	909	-	909	335
Trustees administration expenses	147	-	147	347
Public relations consultancy	13,114	-	13,114	29,253
Legal and professional fees	63,057	-	63,057	10,781
Reporting accountants	-	-	-	86
	<u>77,227</u>	<u>-</u>	<u>77,227</u>	<u>40,802</u>
Total resources expended	<u>95,527</u>	<u>58,257</u>	<u>153,784</u>	<u>112,867</u>
Resources expended by discontinued activities included above:				
Charitable activities				
Twort awards	-	2,383	2,383	2,000
McCord grant	-	12,500	12,500	17,500
Depreciation of endoscopy equipment	-	7,500	7,500	9,000
Maintenance of endoscopy equipment	-	5,606	5,606	7,708
	-	<u>27,989</u>	<u>27,989</u>	<u>36,208</u>

BARRETT'S OESOPHAGUS CAMPAIGN

NOTES TO THE ACCOUNTS (continued) FOR THE YEAR ENDED 30 SEPTEMBER 2010

4. Net incoming (outgoing) resources

	Year ended 30.09.2010	Period to 30.09.2009
	£	£
Net incoming (outgoing) resources for the year is after charging:		
Staff costs	19,550	21,345
Depreciation (in respect of demerged activities)	7,500	9,000
Auditors remuneration (including VAT)	-	-
	<u> </u>	<u> </u>

Staff costs represent the cost of reimbursements made for the provision of staff by a third party. The average weekly number of such staff (excluding Trustees) during the year was 1 (2009: 1).

The Royal Free Hospital Hampstead NHS Trust provides office accommodation on a rent-free basis.

5. Grants and awards

		Grants to institutions	Grants to individuals	Year ended 30.09.2010 Total	Period to 30.09.2009 Total
		£	£	£	£
Medical Research Council	Note (a)	12,500	-	12,500	17,500
Twort awards	Note (b)	-	2,383	2,383	2,000
Barrett's Wessex	Note (c)	(500)	-	(500)	500
		<u>12,000</u>	<u>2,383</u>	<u>14,383</u>	<u>20,000</u>

- (a) This relates to the McCord Prize (worth approximately £85,000 over 3 years) established in 2008 and awarded to Dr Rebecca Fitzgerald and her group in Cambridge to evaluate ultrathin trans-nasal endoscopes compared with conventional endoscopes in the diagnosis and management of Barrett's oesophagus.
- (b) Prizes amounting to £2,000 (2009: £2,000) for research into the diagnosis and management of Barrett's oesophagus were awarded to 4 (2009: 4) individuals during the year. Costs of the event amounted to £383.
- (c) A grant of £500 was made in the period ended 30 September 2009 to the Wessex branch of the Barrett's Support Network for the purposes of providing support for patients. The accounting treatment of the grant which was included as part of resources expended in the previous financial period has been reversed this year. Following the demerger of funds mentioned in the Directors' and Trustees' Report and in Note 6 below, the Wessex branch of the Barrett's Support Network was renamed Barrett's Wessex.

BARRETT'S OESOPHAGUS CAMPAIGN

NOTES TO THE ACCOUNTS (continued) FOR THE YEAR ENDED 30 SEPTEMBER 2010

6. Tangible fixed assets

	Computer equipment £	Endoscopy equipment £	Total £
Cost			
At 1 October 2009	1,244	45,000	46,244
Transferred to HCAS on demerger of funds (see note below)	(1,244)	(45,000)	(46,244)
At 30 September 2010	-	-	-
Depreciation			
At 1 October 2009	1,244	18,000	19,244
Charge for the year	-	5,250	5,250
Transferred to HCAS on demerger of funds (see note below)	(1,244)	(23,250)	(24,494)
At 30 September 2010	-	-	-
Net book value			
At 30 September 2010	-	-	-
At 30 September 2009	-	27,000	27,000

As mentioned in the Directors' and Trustees' Report, agreement was reached during the year for the demerger of funds originally transferred to the charity by the McCord Oesophageal Cancer Foundation, including the division of assets generated since the original merger. The demerger was effected on 30 July 2010 by the transfer of relevant assets and liabilities to a new entity, Heartburn Cancer Awareness & Support ("HCAS"), established for the purposes of the demerger.

7. Debtors and prepayments

	2010 £	2009 £
Other debtors	7,673	55
Prepayments	722	3,622
	<u>8,395</u>	<u>3,677</u>

BARRETT'S OESOPHAGUS CAMPAIGN

NOTES TO THE ACCOUNTS (continued) FOR THE YEAR ENDED 30 SEPTEMBER 2010

8. Creditors: amounts falling due within one year

	2010	2009
	£	£
Loan from trustee (see note below)	29,801	-
Other creditors	-	17,863
Accruals and deferred income	27,350	16,419
	<u>57,151</u>	<u>34,282</u>

The unsecured loan is from Dr Paul Salmon, a trustee, and has been provided to the company on an interest-free basis to meet its liabilities.

9. Restricted Funds

	Balance at 30.09.2009	Incoming resources (Note 2)	Resources expended (Note 3)	Funds demerged (See below)	Balance at 30.09.2010
	£	£	£	£	£
Demerged funds:					
Twort Fund	7,450	7,623	(2,383)	(12,690)	-
McCord Oesophageal Cancer Fund	57,178	12,044	(25,606)	(43,616)	-
Subtotal (demerged funds)	<u>64,628</u>	<u>19,667</u>	<u>(27,989)</u>	<u>(56,306)</u>	<u>-</u>
UK Barrett's Oesophagus Registry (UKBOR)	261	120	(30,630)	-	(30,249)
Barrett's Wessex HALO Equipment Fund	-	14,291	362	-	14,653
	<u>64,889</u>	<u>34,078</u>	<u>(58,257)</u>	<u>(56,306)</u>	<u>(15,596)</u>

As mentioned in the Directors' and Trustees' Report, agreement was reached during the year for the demerger of funds originally transferred to the charity by the McCord Oesophageal Cancer Foundation, including the division of assets generated since the original merger. The demerger was effected on 30 July 2010 by the transfer of the relevant assets and liabilities to a new entity, Heartburn Cancer Awareness & Support ("HCAS"), established for the purposes of the demerger.

Restricted funds relating to UKBOR comprise those funds that are specifically provided for, and expended for the purposes of the operation and management (including database management) of the Registry. Website development relates to those funds specifically donated for and expended on the development of the charity's website www.barrettscampaign.org.uk.

In the directors' opinion, donations received in previous years which should have been ring-fenced for the purposes of UKBOR may have been subsumed into general funds. However, as it is a recognised objective of the charity to secure the future of UKBOR, the directors have proposed that these donations should not be identified for the purposes of these accounts but to redesignate general funds for the purposes of UKBOR as and when it is deemed necessary in the future.

The Barrett's Wessex HALO Equipment Fund represents funds ring-fenced for the purchase of a HALOFLEX Generator for use at Southampton General Hospital in the treatment of Barrett's oesophagus. The equipment was purchased and delivered to Southampton General Hospital in May 2011.

BARRETT'S OESOPHAGUS CAMPAIGN

NOTES TO THE ACCOUNTS (continued) FOR THE YEAR ENDED 30 SEPTEMBER 2010

10. Related party transactions

- a. During the year fees totalling £6,900 (2009: £12,781) were paid to Lawrence Graham LLP. Tim Thornton-Jones, a trustee, is a partner at Lawrence Graham LLP. Trustees are not remunerated for their services as trustees.
- b. Travelling expenses of £147 incurred by Mrs M McCord, a trustee, was reimbursed to her during the year.
- c. Dr P Salmon has advanced various sums to the company amounting to £35,321 on an interest-free basis for it to meet its liabilities. £5,520 was repaid to Dr Salmon during the year and £29,801 was outstanding at the year end.

11. Research projects

Research projects conducted under the auspices of the UK National Barrett's Oesophagus Registry (UKBOR) but administered on its behalf and funded by third parties are not included in the accounts of the Barrett's Oesophagus Campaign.

UKBOR was awarded a research grant of some £93,000 in 2002 to conduct a study of the natural history of Barrett's oesophagus and the influence on that of medical, endoscopic and surgical treatment.

A further £45,000 was received in December 2005. The funding which was provided by the Wexham Gastrointestinal Trust enabled a research fellow to be appointed specifically for this study over three years. At 30 September 2007, the total grant was expended and administration of the project was assumed by The Royal Free and University College Medical School.

During the period ended 30 September 2009, the Wexham Gastrointestinal Trust provided further funding of £10,000 reducing the amount of funds required to be transferred from General Funds and redesignated for the purposes of UKBOR for that period.

BARRETT'S OESOPHAGUS CAMPAIGN

PRESENTATIONS AND PUBLICATIONS (UKBOR)

PAPERS

Published:

1. Caygill CPJ, Reed PI, McIntyre A, Hill MJ (1998). The UK National Barrett's Oesophagus Registry: A Study Between Two Centres. *Eur J. Cancer Prev*; **7**: 161-164.
2. Caygill CPJ, Reed PI, Johnston BJ, Hill MJ, Ali M, Levi S (1999). A single centre's 20 years' experience of columnar-lined (Barrett's) oesophagus diagnosis. *Eur J Gastroent and Hep* **11**: 1355 - 1358.
3. Caygill CPJ, Reed PI, Hill MJ, Watson A (1999) An initial comparison of nine centres registering patients with the UK National Barrett's Oesophagus Registry (UKBOR). *Eur J. Cancer Prev*; **8**: 539-542.
4. Caygill CPJ, Johnston DA, Lopez M, Johnston BJ, Watson A, Reed PI, Hill MJ. (2002). Lifestyle Factors and Barrett's Oesophagus. *Amer J Gastroenterology* **97**:1328-1331.
5. Caygill CPJ, Watson A, Reed PI, Hill MJ (on behalf of the UK National Barrett's Oesophagus Registry (UKBOR) and the twenty seven participating centres)*(2003). Characteristics and Regional Variations of Patients with Barrett's oesophagus in the UK. *Eur J Gastro Hep* **15**: 1217-1222.
6. Van Blankenstein M, Looman CWN, Johnston BJ, Caygill CPJ (2005). Age and sex distribution of the prevalence of Barrett's Esophagus found in a primary referral endoscopy center. *Amer J Gastroenterology* **100**: 568-576.
7. Ramus JR, Gatenby PAC, Caygill CPJ, Watson (2007) *Helicobacter Pylori* infection and severity of reflux-induced oesophageal disease in a cohort of patients with Columnar-Lined Oesophagus *Dig Dis Sci* **52**: 2821-2825.
8. Gatenby PAC, Caygill CPJ, Ramus JR, Charlett A, Fitzgerald R, Watson A (2007) Short Segment Columnar-Lined Oesophagus (CLO) - an underestimated cancer risk? A large cohort study of the relationship between Barrett's CLO segment length and adenocarcinoma risk. *Eur J Gastro Hep* **19**: 969-975.
9. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2007). Does the length of columnar-lined oesophagus change with time? *Dis Oesophagus* **20**: 497-503
10. Ramus JR, Caygill CPJ, Gatenby PAC, Watson (2008) Current UK practice in the diagnosis and management of columnar-lined oesophagus; results of the UK National Barrett's Oesophagus Registry (UKBOR) endoscopist questionnaire. *Eur J Cancer Prev* **17**: 422-425.
11. Gatenby PAC, Caygill CPJ, Ramus JR, Fitzgerald R, Charlett A, Watson A (2008). "Barrett's Columnar-Lined Esophagus: Demographic and Lifestyle Associations and Adenocarcinoma Risk" *Digestive Diseases and Sciences* **53**: 1175-85.

BARRETT'S OESOPHAGUS CAMPAIGN

PRESENTATIONS AND PUBLICATIONS (UKBOR) - continued

12. Gatenby PAC, Ramus JR, Caygill CPJ, Shepherd NA, Watson A (2008). The Relevance of the Detection of Intestinal Metaplasia in Non-Dysplastic Columnar-Lined Oesophagus. *Scand J Gastro* 43: 524-530
13. Gatenby PAC, Ramus JR, Caygill CPJ, Charlett A, Winslet MC, Watson A (2009). Treatment modality and risk of development of dysplasia and adenocarcinoma in columnar-lined esophagus. *Dis oesophagus* 22: 133-42.
14. Ramus JR, Gatenby PAC, Caygill CPJ, Winslet MC, Watson A (2009) Surveillance of Barrett's columnar-lined oesophagus in the UK: endoscopic intervals and frequency of detection of dysplasia. *Eur J Gastro Hep* 21: 636-641.
15. Wall CM, Charlett A, Caygill CPJ, Gatenby PAC, Ramus JR, Winslet M, Watson A (2009). Are Newly Diagnosed Columnar-lined Oesophagus (CLO) Patients Getting Younger? *Eur J Gastro Hep* (in press).
16. Gatenby PAC, Ramus JR, Caygill CPJ, Fitzgerald RC, Charlett A, Winslet MC, Watson A (2009). The Influence of Symptom Type and Duration on the Fate of the Metaplastic Columnar-Lined Oesophagus. *Aliment Pharmacol Ther* 29: 1096-1105.
17. Gatenby PAC, Ramus JR, Caygill CPJ, Shepherd NA, Winslet MC, Watson A (2009). Routinely diagnosed low grade dysplasia in Barrett's oesophagus: A population-based study of natural history. *Histopathology* 54:814-9
18. Gatenby PAC, Ramus JR, Caygill CPJ, Shepherd NA, Winslet MC, Watson A (2009). Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in a multicentre cohort. *Eur J Cancer Prev* 18(5): 381-4.
19. Gatenby P, Hainsworth A, Caygill C, Watson A, Winslet M (2011) Projections for oesophageal cancer incidence in England to 2033. *Eur J Cancer Prev* 20(4): 283-286.
20. Caygill CPJ, Royston C, Charlett A, Wall CM, Gatenby PAC, Ramus JR, Watson A, Winslet M, Hourigan CS, BardhanKD (2011). Barrett's, blood groups and progression to oesophageal cancer: Is nitric oxide the link? *Eur J Gastro Hep* (in press)

MD THESES

1. Gatenby PAC (2008). The Natural History of Columnar-Lined Oesophagus. University of London.
2. Ramus JR (2008). Barrett's oesophagus and its progression to adenocarcinoma. A study of patient profile. University of London

BARRETT'S OESOPHAGUS CAMPAIGN

PRESENTATIONS AND PUBLICATIONS (UKBOR) - continued

LETTERS

1. Fitzgerald R, Caygill CPJ (1999). Treating upper digestive track cancers as a single entity may be misleading. *British Medical Journal (BMJ)* **318**, 1289-90.
2. Caygill CPJ, Watson A (2006) The association of body mass index with Barrett's oesophagus. *Alimt Pharmacol Ther* **23**, 1027-1028.

INVITED PAPERS

1. Caygill CPJ, Reed PI, Watson A, Hill MJ, (2000). "The UK National Barrett's Oesophagus Registry (UKBOR): aims and progress. *Eur J Cancer Prev.* **10**: 97-99.
2. Caygill CPJ (2001). Barrett's Oesophagus and Oesophageal Adenocarcinoma: the Epidemiological Evidence. *Acta Endoscopica* **31**, 485-490
3. Caygill C PJ, Gatenby PAC, Watson A (2010). According to potential sampling errors, should decision of surveillance of columnar-lined oesophagus (CLO) be based upon the presence of intestinal metaplasia (IM) at endoscopy? (in press)

INVITED REVIEWS

1. Reed PI, Caygill CPJ, Watson A, Fitzgerald RC, (2004). The United Kingdom Barrett's Oesophagus Registry (UKBOR) - the first six years. *Gastroenterologia Polska* **10**: 299-304.
2. Caygill CPJ, Watson A, Lao-Sirieix P, Fitzgerald RC (2004). Barrett's Oesophagus and Adenocarcinoma. *World Journal of Surgical Oncology* 2:12. (Web publication) www.wjso.com/content/2/1/12.

REPORTS

1. Caygill CPJ, Zaninotto G, Ruge M (2008) Barrett's Registries in Europe: Report of an International Workshop. *Eur J Cancer Prev.* **17**: 426-429

BARRETT'S OESOPHAGUS CAMPAIGN

PRESENTATIONS AND PUBLICATIONS (UKBOR) - continued

ABSTRACTS AND POSTERS

Published:

1. Caygill CPJ, Reed PI, Hill MJ, Watson A (1997). The UK National Barrett's Oesophagus Registry. *Gut* **40** (suppl.1): A35.
2. Caygill CPJ, Reed PI, Johnston BJ, Hill MJ, Levi S (1997). A Study of Barrett's Oesophagus Registrations From a Single Centre Over a 20 Year Period. *Gut* **41** (suppl.3): E43.
3. Caygill CPJ, Reed PI, Watson A, McIntyre A, Hill MJ (1998). The First Year of the UK National Barrett's Esophagus Registry. *Gastroenterology* **114**, A87.
4. Reed PI, Caygill CPJ, Hill MJ, Watson A (1998). The UK National Barrett's Oesophagus Registry (UKBOR): The first Two Years. *Eur. J. Surgical Oncology* **24**, 457.
5. Caygill CPJ, Reed PI, Hill MJ (1998). UK National Barrett's Oesophagus Registry: A Comparison of Nine Centres. *Digestion* **59** (suppl. 3):580.
6. Watson A, Reed PI, Caygill CPJ, Epstein O, Winslett MC, Pounder RE (1999). Changing incidence of columnar-lined (Barrett's) oesophagus (CLO) in the UK. *Gut* **44**, Suppl. 1, A45.
7. Caygill CPJ, Reed PI, Johnston BJ, Hill MJ, Deru K, Watson A, Levi S (1998) UK National Barrett's Oesophagus Registry : role of obesity, tobacco and alcohol in Barrett's oesophagus. *Eur. J. Cancer Prev.* **7**, 481
8. Watson A, Reed PI, Caygill CPJ, Epstein O, Winslett MC, Pounder RE (1999). Changing incidence of columnar-lined (Barrett's) oesophagus (CLO) in the UK. *Gastroenterology* **116**, Suppl2, A351.
9. Caygill CPJ, Jankowski J, Ali M, Reed PI, Hill MJ (1999). Expression of Bile Acid Receptors: A preliminary report. *Eur. J. Cancer Prev* **8**, 354.
10. Caygill CPJ, Reed PI, Hill MJ, Watson A (1999). The UK National Barrett's Oesophagus Registry: a Progress Report. *Eur. J. Cancer Prev.* **8**, 354
11. Caygill CPJ, Reed PI, Johnston DA, Lopez M, Hill MJ (1999) Obesity and Barrett' s oesophagus in a UK Population. 1999. *Gut* **45**, A81.
12. Caygill C, Reed P, Watson A, Hill M (2000). UK National Barrett's Oesophagus Registry: An Update. *Eur. J Cancer Prev.* **9**: 456-7.

BARRETT'S OESOPHAGUS CAMPAIGN

PRESENTATIONS AND PUBLICATIONS (UKBOR) - continued

13. Caygill C, Reed P, Watson A, Hill M (2000). UK National Barrett's Oesophagus Registry: An Update. *Gut* 47, (suppl. III) A68.
14. Watson A, Caygill CP (2002). The frequency of development of adenocarcinoma in Barrett's oesophagus - implications for surveillance. *Gastroenterology* 122: A350.
15. Van Blankenstein M, Caygill CPJ, Johnston BJ (2002). The prevalence of Barrett's oesophagus (BO) in an U.K. Centre over 15 years. *Gut* 50, (suppl. II) A123
16. Gatenby PAC, Caygill CPJ, Charlett A, Fitzgerald R, Watson A (2003) Length of Barrett's Oesophagus Segment: Demographic Associations and Cancer Risk. *Gut* 52: (suppl. 1) A41.
17. Gatenby PAC, Caygill CPJ, Watson A, Fitzgerald R, Charlett A (2003) Length of Barrett's Oesophagus Segment: Demographic Associations and Cancer Risk. *Gastroenterology* 124: A638.
18. Gatenby P, Caygill C, Ramus J, Bateson M, Johnston D, Fitzgerald R, Watson A (2003) Distribution of obesity by age and gender in Barrett's oesophagus patients at two culturally different centres registering with UK National Barrett's Oesophagus Registry, *J Clin Oncology* 38: 185 (P57). (Selected for oral presentation at plenary session)
19. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A, Fitzgerald RC (2003). Association Between Lifestyle Factors and Histology in Barrett's Oesophagus. *Gut* 52: (suppl VI) A221.
20. Gatenby PAC, Caygill CPJ, Ramus JR, Watson A (2004). Metaplasia-Dysplasia-Adenocarcinoma Sequence in Barrett's Oesophagus (CLO) in a Large UK Series. *Gut* 53: (suppl III) A55.
21. Gatenby PAC, Caygill CPJ, Ramus JR, Watson A (2004). Does the Length of the Columnar-lined Oesophagus (CLO) Change with Time. *Gut* 53: (suppl III) A35. (Selected for plenary session).
22. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Incidence of adenocarcinoma in short and long segment columnar-lined oesophagus. *Gastroenterology* 126: (suppl 2) A308. (awarded a distinction).
23. Gatenby PAC, Caygill CPJ, Ramus JR, Watson A (2004). Does the length of columnar-lined oesophagus (CLO) change with time. *Gastroenterology* 126: (suppl 2) A177. (selected as a poster of special interest).

BARRETT'S OESOPHAGUS CAMPAIGN

PRESENTATIONS AND PUBLICATIONS (UKBOR) - continued

24. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Histological Sequence in a Large UK Series of Columnar-Lined Oesophagus (CLO). *Diseases of the Esophagus* 17: (suppl 1) A22
25. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Histological Sequence in a Large UK Series of Columnar-Lined Oesophagus (CLO). *Diseases of the Esophagus* 17: (suppl 1) A126-7
26. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Adenocarcinoma (AC) Risk in Short (SS) and Long (LS) Segment Columnar-Lined Oesophagus (CLO). *Diseases of the Esophagus* 2004:17 (suppl 1) A46-7
27. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004). Adenocarcinoma (AC) Risk in Short (SS) and Long (LS) Segment Columnar-Lined Oesophagus (CLO). *Diseases of the Esophagus* 17: (suppl 1) A127.
28. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2004), Change in Length of the Columnar-Lined Oesophagus (CLO) over Time and Cancer Risk. *Diseases of the Esophagus* 17: (suppl 1) A16.
29. Gatenby PAC, Ramus JR, Caygill CPJ, Fitzgerald RC, Watson A (2004). Time course of metaplastic and dysplastic changes in columnar-lined oesophagus (CLO) and relationship to symptom onset. Accepted by UEGW Sep. 2004. *Gut* 53 (suppl VI) A99.
30. Gatenby PAC, Ramus JR, Caygill CPJ, Fitzgerald RC, Watson A (2004). Relationship of presenting symptoms to outcome in columnar-lined oesophagus (CLO). *Gut* 53 (suppl VI) A101.
31. Ramus JR, Gatenby PAC, Caygill CPJ, Fitzgerald RC, Watson A (2004). *Helicobacter pylori* infection and severity of oesophageal disease in a cohort of patients with Barrett's oesophagus. Accepted by UEGW for oral presentation. *Gut* 53 (suppl VI) A61.
32. Gatenby PAC, Ramus JR, Caygill CPJ, Watson A (2005). Impact of treatment on Barrett's Cancer incidence. *Gut* 54 (suppl 11) A52.
33. Gatenby PAC Caygill CPJ, Ramus JR, Watson A (2005). Barrett's oesophagus treatment: effect on high grade dysplasia - oesophagageal cancer incidence. *Gastroenterology* 128, (suppl 2), S1713.
34. Gatenby PAC, Caygill CPJ, Ramus JR, Shepherd N, Watson A (2005). The significance of detection of intestinal metaplasia (IM) in columnar-lined oesophagus (CLO). *The Canadian J of Gastroenterology HOME WCOG abstracts* R0078.

BARRETT'S OESOPHAGUS CAMPAIGN

PRESENTATIONS AND PUBLICATIONS (UKBOR) - continued

35. Ramus JR, Gatenby PAC, Caygill CPJ, Watson A (2005). Endoscopic surveillance intervals for columnar-lined oesophagus (CLO) in the U.K. and Impact on detection of dysplastic disease. *The Canadian J of Gastroenterology HOME WCOG abstracts* R0090.
36. Ramus JR, Caygill CPJ, Gatenby PAC and Watson A. (2006). Diagnosis and management of Barrett's oesophagus; results of the UK National Barrett's Oesophagus Registry (UKBOR) endoscopist questionnaire. *Gut* **55** (suppl 11) A104-105.
37. Wall C, Charlett A, Caygill C, Gatenby P, Ramus J, Watson A (2006). Are newly diagnosed columnar-lined oesophagus patients getting younger? *J Clin Gastroenterol* **40** (suppl 4) S207.
38. Gatenby P, Ramus J R, Caygill C P J, Watson A (2007). The Relevance of Low-grade Dysplasia in Columnar-lined Oesophagus. *Gut* **56** (suppl 11) A70.
39. Gatenby P, Ramus J R, Caygill C P J, Watson A (2007). The Outcome of Low-Grade Dysplasia in Barrett's Columnar-Lined Esophagus - A large cohort study from the UK National Barrett's Oesophagus Registry. *Gastrointestinal Endoscopy* **65**: AB133
40. Gatenby PAC; Ramus JR; Caygill CPJ; Winslet MC; Watson A (2008) No Evidence of Aspirin Chemoprotection in Barrett's Adenocarcinoma of the Esophagus? *Gastrointestinal Endoscopy* **67**: AB178-AB179
41. Caygill CPJ, Charlett A, Wall C, Bardhan KD, Royston C, Gatenby P, Ramus JR, Winslet M (2009) Blood group distribution in reflux disease, columnar-lined oesophagus and oesophageal adenocarcinoma compared with the blood donating population. *Gastroenterology* **136**: (Supple 1) A601. (poster of distinction)
42. Ramus JR, Gatenby PAC, Caygill CPJ, Watson A, Winslet M (2009) The risk of smoking on development of dysplastic disease in patients with columnarised oesophagus. (in press)
43. Caygill CPJ, , Royston C, Charlett A, Wall CM, Gatenby PAC, Ramus JR, Watson A, Winslet M, Bardhan K (2010). Mortality in patients with columnar-lined oesophagus (CLO) *Gastroenterology* 2010; 138: S-16 (accepted for oral presentation).
44. Gatenby P, Ramus J, Caygill C, Wall C, Hainsworth A, Watson A, Winslet M (2010). Columnar-Lined Oesophagus Segment Length and High-Grade Dysplasia and Adenocarcinoma Risk. *J Clinl Gastroenterol* 2011; 45: A039.

BARRETT'S OESOPHAGUS CAMPAIGN

PRESENTATIONS AND PUBLICATIONS (UKBOR) - continued

45. Gatenby P, Caygill C, Ramus J, Wall C, Watson A, Winslet M (2010) Same risk of dysplasia but decreasing risk of cancer in Barrett's oesophagus. *J Clinl Gastroenterol* 2011; 45: A038.
46. Gatenby P, Hainsworth A, Caygill C, Watson A, Winslet M (2010) Projections for oesophageal cancer incidence in England. *J Clinl Gastroenterol* 2011; 45: A030.
47. Gatenby P, Caygill CP, Wall C, Bhattacharjee S, Ramus J, , Watson A, Winslet MC and on behalf of the 35 collaborating centres (2011). Lifetime risk of oesophageal adenocarcinoma in patients with Barrett's columnar-lined oesophagus registered with UK National Barrett's Oesophagus Registry. *Gut* 2011; 60: A35
48. Gatenby P, Caygill CP, Wall C, Bhattacharjee S, Ramus J, , Watson A, Winslet MC and on behalf of the 35 collaborating centres (2011). Lifetime risk of oesophageal adenocarcinoma in patients with Barrett's columnar-lined oesophagus registered with UK National Barrett's Oesophagus Registry. *Gastroenterology* (in press)

NOTES

1. Reed PI, Watson A (1996). UK National Barrett's Oesophagus Registry. *Gut*; **39**: 499-500.
2. Reed PI, Watson A (1996). UK National Barrett's Oesophagus Registry. *Eur J Cancer Prev*; **5**: 207.
3. Salmon P (2007) Barrett's Oesophagus Foundation. *Gastrointestinal Nursing*; **5**: 14-17.